The management of multiple sclerosis (MS) in patients with significant comorbidities such as severe asthma presents unique therapeutic challenges. We report a case of successful combined biologic therapy with ofatumumab and mepolizumab in a patient with relapsing MS and pre-existing severe eosinophilic asthma, highlighting the feasibility and safety of dual biologic therapy. To our knowledge, this is the first report of concomitant use of ofatumumab and mepolizumab in a patient with MS and severe eosinophilic asthma, documenting the safety of a non-standard combination strategy in a real-world clinical scenario.
Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab
Zanghi' A;Di Filippo PS;Rutigliano C;Avolio C;D'Amico E.
2025-01-01
Abstract
The management of multiple sclerosis (MS) in patients with significant comorbidities such as severe asthma presents unique therapeutic challenges. We report a case of successful combined biologic therapy with ofatumumab and mepolizumab in a patient with relapsing MS and pre-existing severe eosinophilic asthma, highlighting the feasibility and safety of dual biologic therapy. To our knowledge, this is the first report of concomitant use of ofatumumab and mepolizumab in a patient with MS and severe eosinophilic asthma, documenting the safety of a non-standard combination strategy in a real-world clinical scenario.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
